A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

por Zoulim, Fabien, Moreno, Christophe, Lee, Samuel S., Buggisch, Peter, Horban, Andrzej, Lawitz, Eric, Corbett, Chris, Lenz, Oliver, Fevery, Bart, Verbinnen, Thierry, Shukla, Umesh, Jessner, Wolfgang
Publicado 2018

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

por Marra, Fiona, Höner zu Siederdissen, Christoph, Khoo, Saye, Back, David, Schlag, Michael, Ouwerkerk‐Mahadevan, Sivi, Bicer, Ceyhun, Lonjon‐Domanec, Isabelle, Jessner, Wolfgang, Beumont‐Mauviel, Maria, Kalmeijer, Ronald, Cornberg, Markus
Publicado 2018

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

por Gane, Edward J., DeJesus, Edwin, Janczewska, Ewa, George, Jacob, Diago, Moises, Da Silva, Mariliza Hendrique, Reesink, Henk, Nikitin, Igor, Hinrichsen, Holger, Bourgeois, Stefan, Ferenci, Peter, Shukla, Umesh, Kalmeijer, Ronald, Lenz, Oliver, Fevery, Bart, Corbett, Chris, Beumont, Maria, Jessner, Wolfgang
Publicado 2017